Newsroom Archives - Page 18 of 24 - Spectral Medical Inc

Spectral Medical Announces its Participation at Upcoming Investor Conferences

Toronto, Ontario | August 23, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing diagnostic and therapeutic options for septic shock as well as commercializing a new proprietary platform targeting the...

Spectral Medical Announces Internal Reorganization of its Wholly Owned Subsidiary. Dialco Medical to Enhance Operations and Accelerate Commercialization

Outlines anticipated milestones related to its DIMI and SAMI devices Toronto, Ontario | August 9, 2021 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) today announced an internal reorganization to strengthen the core competencies and management of its...

Spectral Medical Inc. Provides Tigris Clinical Trial Update

Recruitment activity returning to normalized levels with 12 trial sites actively screening patients 15 sites on track to open for enrollment by the end of Q3 2021 TORONTO, July 28, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage...

Spectral Medical Inc. Closes $10 Million Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, July 27, 2021 (GLOBE NEWSWIRE) — Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”), a late stage theranostic company...

Spectral Medical Inc. Announces Overnight Marketed Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | July 20, 2021 – Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce the launch of a proposed overnight marketed...

Dialco Medical Inc. Engages CROMSOURCE as Contract Research Organization Partner for DIMI IDE Trial

TORONTO, Canada – June 7, 2021 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.